The fibroblast growth factor receptor FGFR1 is ectopically expressed in prostate carcinoma cells, but its functional contributions are undefined.
Abstract
The fibroblast growth factor receptor FGFR1 is ectopically expressed in prostate carcinoma cells, but its functional contributions are undefined.
In this study, we report the evaluation of a tissue-specific conditional deletion mutant generated in an ARR2PBi(Pbsn) 
Introduction
Prostate cancer is the most commonly diagnosed cancer in males in the United States and the third leading cause for male cancer patient death (1). Localized prostate tumors can be treated and are not a common cause for patient death. However, prostate cancer patients may develop metastatic tumors in different organs, such as bone, lung, brain and liver etc, and die from metastasis. Currently there is no cure for locally advanced and metastatic prostate cancer.
Accordingly, understanding the molecular mechanisms and biology that mediates prostate cancer progression and metastasis is critically important in the search for novel therapeutic approaches.
In the normal human prostate gland, expression of fibroblast growth factor receptor 1 (FGFR1) is restricted to stroma and is not expressed in epithelial cells (2) . In contrast, foci of prostate cancer exhibit aberrant expression of FGFR1 in epithelial carcinoma cells (3, 4) . In Previous studies have shown that engineered ectopic expression of constitutively active FGFR1 in mouse prostate epithelial cells in a transgenic model resulted in hyperplasia and evolution of pre-malignant prostatic intraepithelial neoplasia (PIN) (5) , and that ectopic expression of FGFR1 in prostate epithelium affected expression of matrix degrading enzymes, including matrilysin (MMP-7) (6), implicating FGFR1 in matrix turnover and cell invasion. Our studies have shown that overexpression of FGF-2 in prostate stromal cells drives elevated angiogenesis, and promotes human prostate cancer xenograft growth (7) . Furthermore, studies using chemical inducers of dimerization (CID) drugs to induce dimerization and activation of an engineered FGFR1 in mouse prostate epithelium resulted in the induction of hyperplasia and PIN (8) that was initially reversible, but progressed over time to adenocarcinoma (9) . In xenograft studies using urogenital sinus mesenchyme recombined with adult prostate epithelial cells, overexpression of dominant negative FGFR1 in epithelial cells led to a reversal of the induction of PIN and prostate cancer by FGF-10 expressed in the mesenchyme (10) . However, since FGFR1 can also form heterodimers with other FGFRs, the specificity of this dominant negative approach remains to be determined. In summary, previous studies have primarily used gain of function approaches with models driven by activation of FGF signaling cascades. Moreover, no
studies have yet addressed the role of FGFR1 in prostate cancer progression to metastasis.
In order to address the significance of FGFR1 in prostate cancer progression and metastases we have used a loss of function knockout approach in the metastatic TRAMP transgenic model of prostate cancer. The TRAMP model exhibits a well-documented step-wise progression of primary tumor to metastatic phenotype with distant metastases to lymph node, lung, liver, and bone (11) (12) (13) . Although this model represents more of a neuroendocrine phenotype at late stages of progression, the model is useful in defining component regulators of metastatic spread. Important for the present study, the TRAMP model exhibits aberrant expression of FGFR1, detected in cancer cells (14) , similar to human prostate cancer. Moreover, the evolution to a neuroendocrine phenotype appears to be important in the emergence of castration resistant disease in human prostate cancer (15) PstI sites. A second set of riboprobes for FGFR1 was similarly generated based on this construct. Antisense riboprobe was generated by in vitro transcription using T3 RNA polymerase on vector linearized with EcoRI, and sense riboprobe using T7 RNA polymerase on vector linearized with BamHI. Both sets of probes produced the same ISH signal. Sense riboprobes exhibited no significant staining patterns ( Supplementary Fig. S3) Statistics. Tumors from each group were analyzed. Average tumor weight was compared between groups for statistical relevance using the Mann-Whitney test (nonparametric). The correlation of tumor genotype with tumor pathology was analyzed using the Fisher's exact test.
The difference of mouse survival was analyzed using the Gehan-Breslow-Wilcoxon test.
Statistical analyses were generated using Graphpad Prism 5.0 (GraphPad Software). P < 0.05 was considered statistically significant.
Results:
Conditional ablation of fgfr1 in prostate tumors in TRAMP model.
In situ hybridization showed that FGFR1 message was localized exclusively in prostate stromal cells with no apparent expression in epithelial cells in normal neo-natal (day 3 postnatal, and all other control mice in an approximately 50% C57BL/6 and 50% FVB background, which is most optimal for prostate carcinoma development and metastasis in the TRAMP model (11) (12) (13) (14) (15) . Necropsy was done in cohorts of mice at either 22 weeks (22-week study) or when prostate tumors evolved to equal 10% of body weight, or the genotype (based on tail DNA). Of these two groups, the fgfr1 KO+ mice primarily exhibited PIN and carcinoma regions with non-detectable FGFR1 message as determined by in situ hybridization ( Fig. 2B and   2C , asterisk), although some well-differentiated cancer foci were positive (Fig. 2C, arrow) .
However, some regions of poorly differentiated foci with positive expression of FGFR1 mRNA were observed in 3 of these 28 KO+ mice ( Fig. 2D and 2E) The fgfr1 KO status also correlated with histopathology, as scored by a pathologist in a genotype-blinded manner (Fig. 2I) . Prostatic intraepithelial neoplasia (PIN), a premalignant phenotype, was detected in 100% of fgfr1 KO+ tumors. Well-differentiated carcinoma foci were detected in 78% of KO+ tumors, phyllodes foci were detected in 15%, and poorly differentiated foci were observed in only 11% of fgfr1 KO+ tumors respectively. In contrast, the fgfr1KO-tumors were positive for PIN in only 25% and well-differentiated cancer foci was detected in only 25% of tumors. Poorly differentiated foci were detected in all (100%) of the fgfr1 KOtumors. The phyllodes phenotype was not observed in any of the fgfr1 KO-tumors. The phenotypic differences between fgfr1 KO+ and fgfr1 KO-tumors in the categories of PIN, welldifferentiated tumor, and poorly differentiated tumor, were each statistically significant (P < 0.05, Fisher's Exact Test for correlation) ( 
histopathology somewhere between the fgfr1 KO+ and fgfr1 KO-extremes in most categories ( Fig. 2I and Table 1 ). Furthermore, while 50% of fgfr1 KO-and 24% of control fgfr1 wt tumors were exclusively poorly differentiated, none of the fgfr1 KO+ tumors were exclusively poorly differentiated. In addition, metastases were observed in all mice with fgfr1 KO-primary tumors, whereas few mice with KO+ primary tumors exhibited metastases.
Control TRAMP tumors, fgfr1 KO+, and KO-tumors exhibited differential patterns of Ki67 immunoreactivity that was associated with different histopathology. The more aggressive fgfr1 KO-tumors with no detectable fgfr1 knockout allele, and some of the control TRAMP tumors exhibit a dense pattern of Ki67 staining that are associated with regions of poor differentiation that are non-necrotic (Fig 3B and 3D) . In contrast, regions of well-differentiated lesions in control TRAMP tumors and all of the fgfr1 KO+ tumors examined, exhibited a focal and heterogeneous staining pattern (Fig. 3A and 3C ). TUNEL staining showed no apparent apoptotic changes in any of the tumor types with exception of the larger and poorly differentiated fgfr1 KO-tumors, which exhibited some regions of focal necrosis (Supplementary Fig. S4 ).
Immunohistochemistry for CD31 showed no apparent differences in vessels (data not shown). Histopathology of recovered tumors at time of death showed that poorly differentiated tumor foci was observed in 100% of fgfr1 KO-tumors, whereas only 38% of fgfr1 KO+ tumors exhibited poorly differentiated foci (Fig. 4F) . The presence of poorly differentiated foci was negatively associated with fgfr1 KO+ tumors (KO+ vs. KO-, p= 0.0090, odds ratio= 0.0335, Fisher's exact test). In addition, 89% of fgfr1 KO-tumors were exclusively poorly differentiated, whereas only 12.5% of fgfr1 KO+ tumors were exclusively poorly differentiated.
In situ hybridization for FGFR1 message revealed a pattern similar to the 22-week study.
fgfr1 KO+ tumors exhibited foci with either no reactivity or some isolated foci with positive reactivity showing some focal escape from excision ( Fig. 4B and 4C ). In contrast, fgfr1 KOtumors were mostly poorly differentiated and all strongly expressed FGFR1 message ( Fig. 4D and 4E). Of interest, phyllodes-like foci (observed in Fig. 4B and 4C) were observed in 75% of fgfr1 KO+ tumors, including 38% that were exclusively phyllodes-like. In contrast, none of the fgfr1 KO-tumors were exclusively phyllodes-like, and only one carried minimal phyllodes-like foci among mostly poorly differentiated foci ( Fig. 4D and 4E) . The phyllodes-like pathology was strongly associated with fgfr1 KO+ tumors (KO+ vs. KO-, p= 0.0152, odds ratio= 24.0, (Fig. 5A ). In concordance with PCR data, in situ hybridization in a subset of samples showed that FGFR1 message was observed in all cancer cells throughout the metastasis (Fig. 5E and 5G ) and metastatic cells were near universally positive for Ki67 (Fig. 3F) . Also of interest, all metastatic tumors exhibited a neuroendocrine phenotype, typical of poorly differentiated TRAMP tumors (16) . Together, these results suggest that FGFR1 signaling is requisite for metastatic spread as no cancer cells with knockout alleles were present in metastases even though many cancer cells with knockout alleles were present in the primary tumors in these same mice. 
Discussion
40% of control TRAMP tumors were poorly differentiated. It is possible that tumors which escape fgfr1 knockout have a significant growth advantage and naturally evolve to a poorly differentiated phenotype. We suspect that escape from fgfr1 knockout resulted in pre-selection of tumor cells that have a more rapid proliferation and are prone to poor differentiation. This may result in an enrichment of the poorly differentiated phenotype (to 100%).
Although specific mechanisms of FGFR1 signaling in prostate cancer cells and the role of this signaling on tumor progression is not yet fully understood, our study clearly suggests that FGFR1 signaling is a key regulator of prostate cancer proliferation, histopathological phenotype, and cancer progression to metastasis. Accordingly, understanding the biology of FGFR1 action and associated signaling pathways in prostate cancer will likely be important in designing novel therapeutic approaches to control evolution of aggressive cancer and the neuroendocrine phenotype, particularly in the context of castration-resistant disease.
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